arrow
D

Don L. Siegel

University of Pennsylvania
H指数:42
被引数:6,689

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

出版更正:CD19 CAR T细胞在B细胞淋巴瘤中的十年持久性

2026-08-260
OAAI
Decade-long persistence of CD19 CAR T cells in B cell lymphomas

CD19 CAR T细胞在B细胞淋巴瘤中的十年持续性

2026-08-100
OA
Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer

泛血液学癌症对嵌合抗原受体 (CAR) T细胞治疗反应的预测生物标志物

2026-03-090
PRE
CCR5-targeted allogeneic gamma–delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy

CCR5靶向的异基因γ-δ CD19嵌合抗原受体T细胞用于HIV相关B细胞恶性免疫治疗

2025-10-210
PRE
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

Bagley SJ, Desai AS, Fraietta JA, Silverbush D, Chafamo D, Freeburg NF, et al. 静脉内双价CAR T细胞靶向EGFR和IL-13Rα2治疗复发性胶质母细胞瘤:一项1期临床试验。Nat Med. (2025). doi: 10.1038/s41591-025-03745-0

2025-06-010
PRE
Cytokine-mediated CAR T therapy resistance in AML

细胞因子介导的AML car-t治疗耐药

2024-09-272
PRE
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication (vol 131, e144486, 2021)
2024-05-011
OAAI
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

抗BCMA/CD19 CAR T细胞与多发性骨髓瘤的早期免疫调节维持对初始或后续治疗有反应

2022-11-2144
OAAI
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
2022-11-0114
OAAI
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

长达十年的白血病缓解与CD4 car-t细胞的持久性

Nature
IF48.5
2022-02-020
PRE